From the mouse cage to human therapy: A personal perspective of the emergence of T-bodies/Chimeric antigen receptor T cells

Human Gene Therapy

Volumn 25, Issue 9, 2014, Pages 773-778

  Eshhar, Zelig ^a,b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIGEN SPECIFICITY; B LYMPHOCYTE; CANCER THERAPY; CELL THERAPY; CLINICAL EFFECTIVENESS; GENE THERAPY; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; ADOPTIVE TRANSFER; ANIMAL; ANTIBODY SPECIFICITY; BIOLOGICAL MODEL; HISTORY; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; NEOPLASMS; PROCEDURES; TRENDS;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODY SPECIFICITY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNOTHERAPY; MICE; MODELS, IMMUNOLOGICAL; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS;

EID: 84907290886     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2014.2532     Document Type: Review

References (33)

1. Bird, R.E., Hardman, K.D., Jacobson, J.W., et al. (1988). Single-chain antigen-binding proteins. Science 242, 423-426.
2. Blat, D., Zigmond, E., Alteber, Z., et al. (2014). Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Mol. Ther. 22, 1018-1028.
3. Chan, C.H., and Stanners, C.P. (2004 ). Novel mouse model for carcinoembryonic antigen-based therapy. Mol. Ther. 9, 775-785.
4. Couzin-Frankel, J. (2013). Breakthrough of the year 2013. Cancer immunotherapy. Science 342, 1432-1433.
5. Dutour, A., Marin, V., Pizzitola, I., et al. (2012). In vitro and in vivo antitumor effect of anti-CD33 chimeric receptorexpressing EBV-CTL against CD33 acute myeloid leukemia. Adv. Hematol. 2012, 683065.
6. Elinav, E., Waks, T., and Eshhar, Z. (2008). Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice. Gastroenterology 134, 2014-2024.
7. Eshhar, Z., Waks, T., Gross, G., and Schindler, D.G. (1993). Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobu lin and T-cell receptors. Proc. Natl. Acad. Sci. USA 90, 720-724.
8. Finkle D., Quan, Z.R., Asghari, V., et al. (2004). HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in femal e murine mammary tumor virus hu-HER2-transgenic mice. Clin. Cancer Res. 10, 2499-2511.
9. Finney, H.M., Lawson, A.D., Bebbington, C.R., and Weir, A.N. (1998). Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161, 2791-2797.
10. Friedmann-Morvinski, D., Bendavid, A., Waks, T., et al. (2005). Redirected primary T cells harboring a chimeric rece ptor require costimulation for their antigen-specific activation. Blood 105, 3087-3093.
11. Friedmann-Morvinski, D., Waks, T., Schindler, D.G., et al. (2014). Adoptive cell therapy of systemic metastases using erbB-2-specific T-cells redirected with a chimeric antibodybased receptor. In Advances in Tumor Immunology and Immunotherapy, Current Cancer Research (Springer Science + Business Media, New York), 107-122.
12. Globerson-Levin, A., Waks, T., and Eshhar, Z. (2014). Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells. Mol. Ther. 22, 1029-1038.
13. Goverman, J., Gomez, S.M., Segesman, K.D., et al. (1990). Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation. Cell 60, 929-939.
14. Gross, G., and Eshhar, Z. (1992). Endowing T cells with antibody specificity using chimeric T cell receptors. FASEB J. 6, 3370-3378.
15. Gross, G., Waks, T., and Eshhar, Z. (19 89). Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. USA 86, 10024-10028.
16. Grupp, S.A., Kalos, M., Barrett, D., et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518.
17. Hombach, A.A., Rappl, G., and Abken, H. (2013). Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 super-stimulation. Mol. Ther. 21, 2268-2277.
18. Huston, J.S., Levinson, D., Mudgett-Hunter, M., et al. (1988). Protein engineering of antibody bind ing sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 85, 5879-5883.
19. Kalos, M., Levine, B.L., Porter, D.L., et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73.
20. Kershaw, M.H., Westwood, J.A., and Hwu, P. (2002). Duals pecific T cells combine proliferation and antitumor activity. Nat. Biotechnol. 20, 1221-1227.
21. Kershaw, M.H., Westwood, J.A., Parker, L.L., et al. (2006). A phase I study on adoptive immunotherapy using gene- modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106-6115.
22. Kochenderfer, J.N., Wilson, W.H., Janik, J.E., et al. (2010). Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099-4102.
23. Kochenderfer, J.N., Dudley,M.E., Feldman, S.A., et al. (2012). Bcell depletion and remissions of malignancy along with cyt okine-associated toxicity in a clinical trial of anti-CD19 chimericantigen-receptor-transduced T cells. Blood 119, 2709-2720.
24. Kochenderfer, J.N., Dudley, M.E., Kassim, S.H., et al. (2014). Chemotherapy -refractory diffuse large B-Cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. [Epub ahead of print]; doi: 10.1200/JCO.2014.56.2 025.
25. Lamers, C.H., Gratama, J.W., Pouw, N.M., et al. (2005). Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implica tions for loss of transgene expression. Hum. Gene Ther. 16, 1452-1462.
26. Lamers, C.H., Sleijfer, S., Van Steenbergen, S., et al. (2013). Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cell s: clinical evaluation and management of on-target toxicity. Mol. Ther. 21, 904-912.
27. Louis C.U.,Savoldo B.,Dotti G.,et al. , 2011, Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma, Blood, 118, 6050-6056.
28. Marcus, A., Waks, T., and Eshhar, Z. (2011). Redirected tumorspecific allogeneic T cells for universal treatment of cancer. Blood 118, 975-983.
29. Matloubian, M., Lo, C.G., Cinamon, G., et al. (2004). Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427, 355-360.
30. Maus, M.V., Grupp, S.A., Porter, D.L., and June, C.H. (2014). Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123, 2625-2635.
31. Porter, D.L., Levine, B.L., Kalos, M., et al. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733.
32. Tammana, S., Huang, X., Wong, M., et al. (2010). 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum. Gene T her. 21, 75-86.
33. Terakura, S., Yamamoto, T.N., Gardner, R.A., et al. (2012). Generation of CD19-chimeric antigen receptor modified CD8 + T cells derived from virus-specific central memory T cells. Blood 119, 72-82.